SpectraCure
1.738 SEK -4.92%1 investor is following this company
SpectraCure is a medical technology company The company specializes in the research and development of medical technology systems used to treat prostate cancer. The cancer treatments are based on proprietary systems that emit laser light sources and photoreactive drugs, a treatment methodology used for internally solid tumors of various types. The company operates in the Nordic market. The head office is located in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SPEC
Daily low / high price
1.606 / 1.828
SEK
Market cap
168.81M SEK
Turnover
192.92K SEK
Volume
110K
Financial calendar
Interim report
14.11.2024
Annual report
20.02.2025
Interim report
15.05.2025
Interim report
15.08.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Masoud Khayyami | 10.0 % | 10.0 % |
Avanza Pension | 5.0 % | 5.0 % |
Cardeon Futuring Fincance AB | 3.2 % | 3.2 % |
Jens Nilsen | 2.5 % | 2.5 % |
Swedbank Försäkring | 1.8 % | 1.8 % |
Nordnet Pensionsförsäkring | 1.8 % | 1.8 % |
Jörgen Wennberg | 1.4 % | 1.4 % |
Pension Futur | 1.2 % | 1.2 % |
Dan Persson | 0.6 % | 0.6 % |
Olle Persson | 0.5 % | 0.5 % |
ShowingAll content types
A well-accomplished annual audit in accordance with ISO 13485:2016
Expert group comments on results of ongoing study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools